Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + atezolizumab + paclitaxel for advanced triple-negative breast cancer
RBR-2x8xh8Phase 3Recruiting
- Sponsor
- Hospital Pérola Byington
- Start
- Jul 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipatasertib, atezolizumab and paclitaxel in triple-negative breast cancer (TNBC) (5 cohorts), sponsored by Hospital Pérola Byington. Started Jul 2019; status: recruiting.
02
Drugs
ipatasertibatezolizumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on RBR-2x8xh8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2x8xh8.